Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
Retrieved on:
Thursday, July 21, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Oncology, National, NIH, Neuropathic pain, Fast track (FDA), CEO, East End (Long Island), Partnership, CNS, Limited, Chronic pain, USD, Help End Marijuana Prohibition (HEMP) Party, Pharmacology, Migraine, Clinical trial, CIPN, ADHD, Pivotal, MD, Patient, European Journal of Pain, Depression, Chemotherapy-induced peripheral neuropathy, Drug development, IND, Pharmaceutical industry, PDPN, Greater China, Mainland China
Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremeds first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain.
Key Points:
- Under the terms of the agreement, Novaremed will grant NeuroFront an exclusive option to obtain exclusive development, commercialization and manufacturing rights to NRD.E1, Novaremeds first-in-class, innovative non-opioid investigational drug candidate for the treatment of neuropathic pain.
- The agreement allows NeuroFront to develop and commercialize NRD.E1 as treatment of painful diabetic peripheral neuropathy (PDPN) and any other neuropathic pain indications in the Greater China territory (including Mainland China, Hong Kong, Macau, and Taiwan) and Singapore.
- We are very delighted collaborating with NeuroFront to advance our non-opioid neuropathic pain treatment for patients suffering from PDPN and other neuropathic pain indications in China.
- NeuroFront is very excited to partner with Novaremed to change the lives of many PDPN patients in Greater China and Singapore.